In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05 ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Explore Roivant Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ROIV. Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9 ...

NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market capitalization of $7.61 billion, a price-to ...

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...

As the broader market continues to rise this year, we thought it would be […] BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the ...